A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults
NN6022-7683
Phase 1 other active
Quick answer
A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults for Cardiometabolic diseases is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Cardiometabolic diseases
- Phase
- Phase 1
- Modality
- other
- Status
- active